Last reviewed · How we verify
NCT05466760
PET/MR Radiomics for Breast Cancer Diagnosis
trial testing PET/MR in Breast Cancer in 120 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Taipei Veterans General Hospital, Taiwan |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 6 July 2018 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- PET/MR
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Taipei Veterans General Hospital, Taiwan
Who can join
Adults 25 to 75, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Breast cancer is the most common malignancy in women in our country (2013 cancer registry report, Health Promotion Administration). MRI is a more accurate imaging modality for breast lesion diagnosis, monitoring of treatment response, and local staging than compared with mammography and ultrasound. ¹⁸ F-FDG PET was reported to be used for breast cancer diagnosis, staging, and prediction of treatment response as well. We usually interpret the aforementioned imaging modalities by qualitative methods for decision-making. Radiomics is a process involving the conversion of images to quantitative data for subsequent data mining to improve decisional making for patient care, to adjust the patient management, that is so-called precision medicine. Our study is to use semantic and agnostic features of radiomics by hybrid PET/MR for 1. The pre-operative breast cancer patients (without neoadjuvant chemotherapy before operation). 2. The patients will receive neoadjuvant chemotherapy (NAC). The study intends to investigate the association of PET/MR radiomics data with the probability of metastasis or risk of recurrences and survival. We will also investigate if the BD and BPE (measured on MRI) are associated with molecular subtypes, histologic grade and clinical outcome, risk of metastases, and long-term survival of breast cancer patients for the study participants.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Delta radiomics: an updated systematic review.
Nardone V, Reginelli A, Rubini D, Gagliardi F, et al · · 2024 · cited 28× · PMID 39017760 · DOI 10.1007/s11547-024-01853-4
Verify or expand the search:
- PubMed search for NCT05466760
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET/MR
Trials testing the same drug.
- NCT06092125 — Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease · recruiting
- NCT05006326 — Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma · NA · unknown
- NCT04271436 — Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT · Phase 2 · withdrawn
- NCT04552847 — Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors · Phase 2, PHASE3 · completed
- NCT04271254 — PET/MR Characterization of Renal Cell Carcinomas · NA · terminated
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Taipei Veterans General Hospital, Taiwan trials
Trials by the same sponsor.
- NCT07463443 — Effectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Stud · NA · not yet recruiting
- NCT07400757 — Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease · NA · not yet recruiting
- NCT07362134 — Pulsed-Field Ablation for Recurrent Atypical Atrial Flutter · NA · enrolling by invitation
- NCT07473687 — Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room · recruiting
- NCT07344207 — GUARD-PH: Guided Use of AI-ECG for Risk Detection of PH in Surgery (GUARD-PH Trial) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05466760 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Veterans General Hospital, Taiwan
- Last refreshed: 20 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05466760.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing